Heat map of patient characteristics and secondary lesions. The primary, primary xenografted, and serial xenografted ALL samples are displayed by the ABL-class tyrosine kinase gene from the most sensitive (left) to the least sensitive (right) based on the area under the dose-response curve (AUC) for imatinib measured using an ex vivo imatinib sensitivity assay. Deletions and other aberrations in leukemia-associated genes, PAX5, IKZF1, CDKNA2A/B, and pseudoautosomal (PAR) regions, based on MLPA assays or whole-exome sequencing are shown. IKZF1 deletions are subdivided into deletions resulting in haploinsufficiency (in dark green, affecting the start codon in exon 2) and deletions that affect the DNA-binding domain, exerting a dominant-negative effect on the unaffected allele (in dark red, deletions of exons 4-7). A white square in the middle denotes no mutations but whole-exome sequencing data available, a diagonal white line denotes no deletions but MLPA data available, and gray squares denote no data available.